www.clinicaltrials.gov

1 Not yet recruiting

A Study Investigating the Safety and Tolerability of
Deferiprone in Patients With Friedreich's Ataxia
Condition: Friedreich's Ataxia
Interventions: Drug: placebo; Drug: deferipone;
Drug: deferiprone

2 Active, not recruiting

Idebenone to Treat Friedreich's Ataxia
Condition: Friedreich Ataxia
Intervention: Drug: Idebenone

3 Completed

Transitional Life Events in Patients With Friedreich's
Ataxia: Implications for Genetic Counseling
Condition: Friedreich Ataxia
Intervention:

4 Completed

Phase 1 Trial of Idebenone to Treat Patients With
Friedreich's Ataxia
Condition: Friedreich Ataxia
Intervention: Drug: Idebenone

5 Recruiting

Study to Assess the Efficacy, Safety and Tolerability
of Idebenone in the Treatment of Friedreich's Ataxia
Condition: Friedreich's Ataxia
Interventions: Drug: Idebenone; Drug: Idebenone;
Drug: Placebo

6 Active, not recruiting

Efficacy of Epoetin Alfa in Patients With Friedreich's
Ataxia
Condition: Friedreich's Ataxia
Intervention: Drug: Epoetin alfa

7 Completed

Safety Study of Idebenone to Treat Friedreich's Ataxia

Condition: Friedreich Ataxia
Intervention: Drug: Idebenone

8 Active, not recruiting

Iron-Chelating Therapy and Friedreich Ataxia
Condition: Friedreich Ataxia
Intervention: Drug: Iron chelating intervention





Friedreich's Ataxia Research Alliance (FARA)
P. O. Box 1537 Springfield, VA 22151
Tel                (703) 426-1576        ; http://www.CureFA.org

FA Patient Registry: http://curefa.org/registry/
E-Bulletin Sign-up: http://curefa.org/news/index.asp

VIEW THE LATEST NEWSLETTER, The Advocate
http://www.curefa.org/docs/newsletter_2007-2008_winter.pdf



________________________________________________________________________________\
____

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top